X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) Shares Acquired by State Street Corp

State Street Corp lifted its stake in shares of X4 Pharmaceuticals, Inc. (NASDAQ:XFOR) by 6.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,952,895 shares of the company’s stock after purchasing an additional 189,105 shares during the quarter. State Street Corp owned about 1.75% of X4 Pharmaceuticals worth $1,976,000 at the end of the most recent quarter.

Several other hedge funds have also recently modified their holdings of XFOR. Verition Fund Management LLC acquired a new position in X4 Pharmaceuticals during the 3rd quarter worth approximately $30,000. SG Americas Securities LLC purchased a new stake in shares of X4 Pharmaceuticals in the third quarter valued at approximately $37,000. XTX Topco Ltd acquired a new position in X4 Pharmaceuticals during the second quarter worth $65,000. Rhumbline Advisers raised its position in X4 Pharmaceuticals by 14.6% in the second quarter. Rhumbline Advisers now owns 187,246 shares of the company’s stock worth $109,000 after acquiring an additional 23,831 shares in the last quarter. Finally, AQR Capital Management LLC lifted its holdings in X4 Pharmaceuticals by 1,080.3% in the second quarter. AQR Capital Management LLC now owns 424,042 shares of the company’s stock valued at $246,000 after acquiring an additional 388,115 shares during the period. 72.03% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In related news, COO Mary Dibiase sold 67,695 shares of the stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $0.57, for a total transaction of $38,586.15. Following the completion of the sale, the chief operating officer now owns 452,060 shares of the company’s stock, valued at approximately $257,674.20. This represents a 13.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Paula Ragan sold 239,436 shares of the firm’s stock in a transaction that occurred on Monday, October 7th. The shares were sold at an average price of $0.55, for a total transaction of $131,689.80. Following the completion of the transaction, the chief executive officer now owns 1,057,713 shares in the company, valued at $581,742.15. The trade was a 18.46 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 580,800 shares of company stock valued at $321,447 over the last quarter. Company insiders own 1.62% of the company’s stock.

Wall Street Analyst Weigh In

XFOR has been the topic of a number of recent analyst reports. Stifel Nicolaus lowered their price target on shares of X4 Pharmaceuticals from $5.00 to $4.00 and set a “buy” rating on the stock in a research note on Thursday, November 14th. HC Wainwright lowered their target price on shares of X4 Pharmaceuticals from $5.00 to $1.50 and set a “buy” rating on the stock in a research report on Thursday, November 14th.

X4 Pharmaceuticals Price Performance

XFOR opened at $0.73 on Thursday. X4 Pharmaceuticals, Inc. has a 1 year low of $0.26 and a 1 year high of $1.60. The company’s 50 day simple moving average is $0.53 and its 200 day simple moving average is $0.63. The stock has a market capitalization of $125.11 million, a PE ratio of -8.15 and a beta of 0.35. The company has a debt-to-equity ratio of 1.26, a quick ratio of 4.80 and a current ratio of 4.89.

X4 Pharmaceuticals Company Profile

X4 Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, focuses on the research, development, and commercialization of novel therapeutics for the treatment of rare diseases. Its lead product candidate is mavorixafor, a small molecule inhibitor of the chemokine receptor C-X-C chemokine receptor type 4 (CXCR4), which is in Phase III clinical trial for the treatment of patients with warts, hypogammaglobulinemia, infections, and myelokathexis syndrome; and Phase II clinical trial to treat congenital, idiopathic, or cyclic neutropenia.